Liquid Biopsy: A New Emerging Technique

Abstract

Liquid biopsy contrary to tissue biopsy utilizes samples of blood, urine, or other body fluid to look for cancer cells from a tumor or small pieces of DNA, RNA, or other molecules released by tumor cells into a person's body fluids. Liquid biopsy is a new test with several potential advanced uses in cancer treatment, with a few U.S. Food and Drug Administration (FDA)-approved uses. Research into its benefits is continuing [1]. Prostate cancer (PCa) is common in men and can be localized or aggressive. Biomarkers such as PSA has limited specificity and sensitivity. There is an urgent need for better biomarkers that can differentiate benign from malignant prostate conditions, localized from metastatic as well as aggressive from slow disease.